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This study determined, by molecular typing of C. albicans species isolated from denture stomatitis patients with a mycological relapse six
months after successful itraconazole therapy, whether there had been recurrence of infection with the same strain(s), selection of particular
strains or infection with new strains of C. albicans. Forty patients with long-standing Candida-associated denture stomatitis were assigned
either cyclodextrin itraconazole solution or itraconazole capsules (100mg b.d. for 15 days). Palatal erythema was measured and imprint
cultures undertaken at baseline and at 15 days, four weeks and six months after treatment commenced. Yeast isolates were formally
identified and chromosomal DNA was extracted from pairs of isolates from those patients with C. albicans present at baseline and six
months after treatment commenced. Southern blotting of EcoRI-digested chromosomal DNA was performed using the C. albicans-spe-
cific 27A repetitive element as a probe. Eighteen of 36 patients were infected with C. albicans at baseline and six months after treatment
commenced. Overall, 13 genetically different strains of C. albicans were found. However, in 17 of 18 patients, the C. albicans strains
isolated prior to itraconazole therapy and six months later were the same. Thus recurrence of denture stomatitis in these individuals was
due to re-colonisation by the original strain, rather than re-infection with a different strain. Key words : Genotyping, C. albicans, denture
stomatitis.
ORIGINAL ARTICLE
INTRODUCTION
Candida-associated denture stomatitis, characterised by
erythema and oedema of the palatal mucosa beneath an
upper denture, affects 50% of denture wearers (1). Nys-
tatin, amphotericin B, miconazole and fluconazole have
been used in the management of denture stomatitis, but
the recurrence rate is high (2). Itraconazole has been
effective in the management of oral candidosis among
immunocompromised patients (3) and a pilot study
showed itraconazole capsules to have comparable efficacy
to fluconazole capsules in the management of denture
stomatitis (4). Furthermore, both the new liquid formula-
tion of itraconazole in hydroxypropyl-b-cyclodextrin and
itraconazole capsules have been found to produce similar
reductions in palatal erythema and yeast colonisation in
patients with Candida-associated denture stomatitis, but
rarely a long term mycological cure (submitted for publica-
tion). Molecular typing of yeasts isolated from denture
stomatitis patients before and after antifungal therapy may
permit a fuller understanding of the reasons for any re-
lapses following treatment.
Methods of typing clinical isolates of C. albicans are
useful in determining whether commensally carried strains
are the source of infection, whether there are particular
strains adapted to particular body niches and whether a
new episode of the disease is caused by reinfection or
relapse (5). It has been suggested that DNA typing is one
of the methods with the greatest potential for discrimina-
tion (6). DNA fingerprinting was first applied to yeasts by
Scherer and Stevens (7) who examined 17 isolates of C.
albicans, 10 C. tropicalis, seven C. parapsilosis, one C.
krusei and one C. pseudotropicalis. DNA typing of C.
albicans by restriction fragment length polymorphisms
(RFLP) and DNA probes have been well documented (8)
and recently, the polymerase chain reaction (PCR) has
been used to characterise Candida species (9). Mathaba et
al. (10) determined the genotypic relationships of individ-
ual C. albicans isolates by hybridisation of a C. albicans-
specific moderately repetitive sequence, 27A, to EcoRI-
digested C. albicans chromosomal DNA. They concluded
that denture stomatitis was due to the overgrowth of
commensal strains in the oral cavity and that no one
particular virulent strain of C. albicans was associated with
denture stomatitis. Furthermore, in five of the 18 patients
studied, C. albicans isolates were obtained from a sec-
ondary infection which occurred after antifungal therapy.
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It was concluded that this was due either to the re-emer-
gence of the original infecting strain or the emergence of
a new strain from an exogenous source, or both. The
type of antifungal therapy used in this study was not
specified.
In order to permit a fuller understanding of mycologi-
cal relapse of denture stomatitis following antifungal ther-
apy, C. albicans strains isolated from patients at baseline
and six months after itraconazole treatment commenced
were genetically typed to determine whether there was a
recurrence of infection with the same strain, selection of
particular strains or infection with new strains.
MATERIALS AND METHODS
Edentulous denture wearers with long-standing Candida-
associated denture stomatitis were studied. Patients were
recruited from the Prosthodontic and Oral Medicine De-
partments of Glasgow Dental Hospital and School NHS
Trust. To be eligible for enrollment, patients had to be
edentulous denture wearers with clinical evidence of den-
ture stomatitis and positive yeast cultures from the
palatal mucosa and dorsum of the tongue. Forty patients
were enrolled and received either cyclodextrin solution of
itraconazole (Sporanox Liquid®, Janssen Pharmaceuti-
cals) at an oral dose of 100mg twice daily for 15 days, or
itraconazole capsules (Sporanox®, Janssen Pharmaceuti-
cals) at an oral dose of 100mg twice daily for 15 days. In
addition, all patients were instructed in denture hygiene
measures. At baseline, an objective measurement of
palatal erythema was obtained by means of an electro-op-
tical instrument, the Erythema meter, which provided an
‘erythema index’ (11). Imprint cultures (12) of the palatal
mucosa, tongue and denture fitting surface and an oral
rinse specimen (13) were collected and inoculated onto
Sabouraud’s dextrose agar (Life Technologies, Paisley,
Scotland) and CHROMagar® Candida (Life Technologies,
Paisley, Scotland). Microbiological samples were not
taken from any other body sites. Clinical outcomes were
assessed at 15 days, four weeks and six months after
treatment commenced by recording changes in the ‘ery-
thema index’. The microbiological samples were repeated
at the same time intervals.
One colony of each morphological type on CHROMa-
gar® Candida was plated for purity, identified and stored
at 70°C. For each patient, four further colonies were
removed from the Sabouraud’s plates, selected at random
from the specimens available. Each isolate was formally
identified and stored at 70°C for further investigation.
C. albicans was identified on the basis of germ tube
production. A sucrose assimilation test was performed on
germ tube positive yeasts to distinguish C. albicans from
C. stellatoidea. Germ tube negative yeasts were identified
by the API 32C test (Bio-Me´rieux S A, Marcy-l’Etoile,
France).
DNA extraction
Pairs of isolates from those patients with C. albicans
present at baseline and six months after treatment com-
menced, were selected at random, removed from storage at
70°C and plated onto Sabouraud’s agar. The
Sabouraud’s plates were incubated at 37°C for 48 h. DNA
was extracted using a method similar to one based partly
on that originally devised by Scherer and Stevens (7), as
described by Anthony et al. (14). Growth from a
Sabouraud’s plate was emulsified in 10ml YEPD broth
(0.3% yeast extract, 1% mycopeptone, 2% dextrose) and
incubated overnight at 30°C in an orbital incubator. Cells
from 1.5ml of the broth were pelleted in a centrifuge, the
supernatant removed, and the cells washed by resuspend-
ing in 1000ml 1M sorbitol. Cell walls were digested by
re-suspending in 1M sorbitol plus 50mM K2HPO4 (pH
7.5) and adding to each tube 3ml b-mercaptoethanol and
20ml of freshly prepared 20mg:ml lyticase 20T (Sigma
Chemical Company Limited, Dorset, UK) in 1M sorbitol
and incubating at 37°C for 90 minutes. The resulting
spheroblasts were pelleted by centrifugation at 13000
r.p.m., the supernatant removed and lysed by adding 0.5ml
GES reagent (30g guanidium thiocyanate dissolved at
65°C in 20ml 0.5mol:l EDTA at pH 8 and then 2.5ml of
10% w:vol sarkosyl added, finally made up to 50ml with
distilled water) (15). After 20 minutes at room tempera-
ture, samples were centrifuged for 3 minutes and the
supernatant retained. The supernatant was extracted once
with an equal volume of phenol:chloroform (1:1), potas-
sium acetate was then added to a final concentration of
2.5M and the mixture extracted once with an equal volume
of chloroform:pentanol (24:1). DNA was precipitated with
an equal volume of isopropanol at 70°C for 30 minutes,
pelleted and resuspended in TE buffer (10mM TrisHCL,
1mM EDTA, pH 7.5). RNA was removed by incubation
with 5mg:ml RNAase A stock solution at 37°C for 15
minutes and DNA re-precipitated with isopropanol. DNA
was quantitated by agarose gel electrophoresis.
Southern blotting
Two to three micrograms of C. albicans chromosomal
DNA was digested with 30 units of EcoRI (Life Technolo-
gies, Paisley, UK) and electrophoresed on a 0.8% agarose
gel in 1TBE buffer (10.8g Tris Base, 5.5g Boric acid,
0.746g EDTA). DNA fragments were transferred to posi-
tively-charged nylon membranes (Boehringer Mannheim,
Lancs., UK) by Southern blotting (16). Briefly, gels were
prepared for blotting by soaking in 250ml of denaturation
solution (0.5M NaOH:1.5M NaCl) for 220 minutes
followed by soaking in 250ml of neutralisation solution
(0.5M tris-HCl, pH 7.4) for 220 minutes. DNA was
transferred to membranes using a capillary blotting unit
(Anachem Ltd., Luton, UK) using 20SSC (3.0M NaCl:
0.3M sodium citrate, pH 7.0) as a transfer buffer. Follow-
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ing transfer, membranes were rinsed in 20SSC and
DNA immobilised by exposure to an optimal dose of UV
energy in a cross-linker (UVC-508; Anachem Ltd., Luton,
UK).
Following prehybridisation at 68°C for 4 hours in stan-
dard hybridisation solution (5SSC, 0.1% N-lauroylsar-
cosine, 0.02% sodium dodecyl sulphate, 1% blocking
reagent), membranes were then hybridised with the C.
albicans-specific 27A repetitive element labelled with
digoxigenin (DNA labelling and detection kit; Boehringer
Mannheim) at 25ng:ml in standard hybridisation buffer
(17). The 27A repetitive element originally described by
Scherer and Stevens (7) was kindly provided by Dr. B.B.
Magee (University of Minnesota).
Following hybridisation, membranes were washed at
room temperature in 2SSC: 0.1% SDS for 25 min-
utes, and then 68°C in 0.1SSC: 0.1% SDS for 215
minutes. Immunological detection of hybridised DNA
fragments was carried out in accordance with the manu-
facturer’s instructions using an anti-digoxigenin antibody
conjugated to alkaline phosphatase and colorimetric detec-
tion with 4-nitroblue tetrazolium chloride:5-bromo-4-
chloro-3-indolyl-phosphate as a colour substrate.
RESULTS
A total of 40 denture stomatitis patients entered the study.
However, two patients from each treatment group failed to
complete the course of itraconazole and were excluded
from all efficacy analyses. Both forms of itraconazole
resulted in a generalised reduction in erythema which was
seen in most patients throughout the clinical trial (data
submitted for publication).
C. albicans was isolated from all patients before treat-
ment commenced. All of the C. albicans strains isolated at
baseline were found to be susceptible to itraconazole (18)
by means of a broth dilution assay (19). The mean itra-
conazole minimum inhibitory concentration (MIC) for the
C. albicans species isolated at baseline was 0.16mg:L
(range 0.06–0.25 mg:L).
A mycological cure was achieved, at all sites sampled, in
17 of the 36 patients on completion of the two week course
of itraconazole. Four weeks after treatment commenced,
13 patients remained yeast free and seven were still myco-
logically cured six months after treatment commenced.
Although no patients had an increased yeast count on
completion of the itraconazole therapy, eight patients in
total had higher yeast counts by four weeks and six
months after treatment commenced than had been
recorded at baseline (data submitted for publication).
Of the 36 patients who completed the clinical trial, 18
were colonised with C. albicans at baseline and six months
after treatment commenced. Chromosomal DNA was ex-
tracted from 36 stored C. albicans isolates in total, two
isolates from each of the 18 patients, one which had been
collected at baseline and another collected six months after
treatment commenced. Although C. albicans was isolated
from these 18 patients at baseline and at the end of the
trial, nine of these patients had been completely mycologi-
cally cured at either two weeks or four weeks after treat-
ment commenced, five of the nine being completely yeast
free at both of these visits. A further two of the 18 patients
were free of C. albicans at two weeks and four weeks after
itraconazole therapy, although other yeast species, C.
glabrata in one case and S. cere6isiae in the other, per-
sisted. Although C. albicans persisted in the remaining
seven patients throughout the clinical trial, yeast counts
were reduced following itraconazole therapy in six of these
seven patients.
Hybridisation of the 27A repetitive element probe to the
DNA samples digested with EcoRI allowed differentiation
of the strains of C. albicans (Fig. 1). Use of the C. albicans
27A probe revealed only minor differences in band pat-
terns between pre- and post-treatment isolates in all but
one case, indicating that, in 17 of 18 patients, the C.
albicans strains isolated prior to itraconazole therapy and
six months after treatment commenced were the same. Any
differences in band pattern between strains from the same
patient were usually subtle when compared to the major
differences seen among strains from different patients. For
example, lanes 9 and 10 (Fig. 1) are C. albicans isolates
taken from the same patient at baseline (lane 9) and six
months after treatment commenced (lane 10). The band
patterns of these two isolates are almost identical and were
considered to be the same strain. However, comparison of
isolates taken from different patients, for example, lanes 5,
9 and 11 in Fig. 1, reveals a significantly different band
pattern in each lane implying that different strains of C.
albicans have been isolated from each of these patients.
Only one patient appeared to have a different strain of C.
albicans isolated at baseline (lane 3) than at six months
after treatment started (lane 4). Among this group of
eighteen patients, thirteen completely different strains of
C. albicans were detected. Of these thirteen strains, four
were carried by more than one patient.
DISCUSSION
Progressive recolonisation of the mucosa and the denture
fitting surface by yeasts and the consequent recurrence of
denture stomatitis after completion of antifungal treatment
has been reported (20–23). In the present study, both
forms of itraconazole resulted in a reduction in erythema
of the palatal mucosa, although the Erythema meter in-
dices, in both treatment groups, remained higher after
antifungal treatment than the indices found in patients
with no history of denture stomatitis (4). Seven of 36
patients who completed the clinical trial remained myco-
logically cured after completing the course of itraconazole
therapy until the end of the trial. A further patient who
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was free of yeasts four weeks after treatment commenced
remained so six months later. However, 50% of patients
who had been mycologically cured at two or four weeks
after treatment commenced were recolonised by yeasts at
six months. Genetic typing of C. albicans strains isolated
from these patients at baseline and six months after treat-
ment has shown that, in all but one case, the same strain
of C. albicans was present before treatment as at the end of
the clinical trial.
The aim of this study was to determine, by molecular
typing of C. albicans species isolated before and after
treatment, whether there had been a recurrence of infec-
tion with the same strain, selection of particular strains or
infection with new strains of C. albicans. In the past it was
difficult to answer this type of question as strain compari-
sons were based on phenotypes rather than genotypes,
with the assumption that the underlying genetic differences
that produced the phenotypic changes were the same in
different isolates (7). The advent of recombinant DNA
technology has meant that genetic assessments of strain
relatedness are now possible, overcoming the risk of
grouping together genetically unrelated strains with similar
phenotypes and separating related strains with different
phenotypes. One of the most effective of these techniques
has been Southern blot hybridisation with DNA probes
containing moderately repetitive sequences (24). The C.
albicans middle repetitive 27A sequence was chosen as this
has been shown to be a very sensitive method of analysing
DNA samples digested with restriction enzymes (5).
EcoR1 was chosen as the enzyme for the digestion of the
DNA because it has been suggested as the enzyme of
choice for greatest discrimination when using the 27A
probe (5, 14).
For every patient enrolled in the trial, at least five yeast
isolates per visit had been stored at 70°C for further
investigation. Although C. albicans was not the only spe-
cies isolated from this study population it is considered to
be the main pathogen in oral candidosis and, as at the time
of this study corresponding species-specific repeat sequence
probes had not been developed for other Candida species
(25), it was decided to concentrate only on C. albicans for
the molecular investigations. In this study there were 18
patients from whom C. albicans was isolated six months
after treatment commenced as well as at baseline. Two
isolates from each patient, one collected at baseline and
one six months after treatment commenced, were selected
at random and removed from storage. Although some
studies have found that the majority of C. albicans isolates
from different sites within the same oral cavity have been
found to belong to the same genetic group (10), other
Fig. 1. Southern blot obtained, showing the C. albicans-specific 27A repetitive element probe hybridised to EcoR1 digested C. albicans
DNA. Lanes 1 to12 show samples of digested DNA from C. albicans isolates taken from six of the study patients. Each pair of lanes
represents C. albicans DNA extracted from isolates from the same patient. In any pair of lanes, the first lane represents digested DNA
from yeasts isolated at baseline and the second lane represents DNA from yeasts isolated six months after treatment commenced. M is
a standard base pair (Bp) marker for gel electrophoresis ie. lDNA digested with EcoRI and Hind III.
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studies have reported that some patients may carry more
than one strain of C. albicans (14). In this study, as far as
possible, the isolate collected six months after treatment
commenced was from the same intra-oral site as the base-
line isolate with which it was to be compared. This was to
overcome the chance of ‘sampling error’ which may have
given the impression that a different strain was present at
the six month review than at baseline, when actually
multiple strains may have been present at different intra-
oral sites for much of the time.
In this study, 13 different strains of C. albicans were
isolated from the 18 patients. This genetic diversity is
similar to that found in other studies of C. albicans strains
isolated from the oral cavities of non-immunocompro-
mised individuals (10, 24). For 17 of 18 volunteers with a
mycological relapse, the strain of C. albicans isolated six
months after itraconazole treatment commenced was con-
sidered to be genetically the same as the original strain
isolated at baseline. The number of band differences
judged acceptable for two isolates to be classified as identi-
cal strains has been interpreted differently by different
workers (10, 14). Anthony et al. (14) identified minor
differences between multiple isolates from a single patient,
but these changes were subtle when compared to changes
between strains from different patients. These authors
concluded that restriction fragment length polymorphism
types, differing by less than three bands, seen in isolates
from individual patients were due to genetic recombination
within a single strain. The same criteria have been used to
interpret the genetic typing results found in this study.
In the study by Mathaba et al. (10) the C. albicans
strains isolated from the dentures during the primary
infection were the same as those isolated during the sec-
ondary infection, following a course of antifungal therapy,
in nine out of 11 patients. This implies that the presence of
C. albicans in these patients is typically due to re-colonisa-
tion by the original infecting strain rather than re-infection
with a different strain. Although the primary reservoir of
Candida species in healthy individuals is generally consid-
ered to be the gastro-intestinal tract (26), the patient’s
denture must be considered a potential source of re-infec-
tion, a view shared by other authors (22, 27, 28). This
further supports the conclusion that the provision of new
dentures is an important factor in the long-term resolution
of denture stomatitis.
The variety of genotypes identified in this study, as in
the study by Mathaba et al. (10), suggests that no one
particular virulent strain of C. albicans is associated with
denture stomatitis. However, it would be interesting to
compare the genotypes of C. albicans isolates from denture
wearers with healthy palatal mucosa and those from den-
ture wearers with denture stomatitis, in an attempt to
determine whether commensal strains of C. albicans are
capable of causing an infection or whether, in the transi-
tion from a healthy to an infected mouth, there is strain
substitution.
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